Literature DB >> 16677065

Epidemiology of osteoporosis in women with cognitive impairment.

Sarina Schrager1.   

Abstract

Osteoporosis is increasing due to the aging of the population. Women with cognitive impairment from childhood are at disproportionally high risk for osteoporosis and fractures. Suggested explanations for this increased risk include high use of anticonvulsant medications, lower peak bone densities, and higher rates of nonambulation. Down syndrome seems to be an independent risk factor for low bone density and fractures, presumably due to lower muscle tone. Here, the limited information available on the epidemiology of osteoporosis in the general population and in women with cognitive disabilities is briefly reviewed. Health care professionals should consider women with cognitive disabilities at high risk for osteoporosis and fractures. Studies are needed to determine screening regimens and prevention strategies appropriate for women in this population.

Entities:  

Mesh:

Year:  2006        PMID: 16677065     DOI: 10.1352/0047-6765(2006)44[203:EOOIWW]2.0.CO;2

Source DB:  PubMed          Journal:  Ment Retard        ISSN: 0047-6765


  4 in total

Review 1.  Screening tests for adults with intellectual disabilities.

Authors:  Joanne E Wilkinson; Larry Culpepper; Mary Cerreto
Journal:  J Am Board Fam Med       Date:  2007 Jul-Aug       Impact factor: 2.657

2.  Fracture risk in people with developmental disabilities: results of a large claims data analysis.

Authors:  G Büchele; C Becker; I D Cameron; R Auer; D Rothenbacher; H H König; K Rapp
Journal:  Osteoporos Int       Date:  2016-08-24       Impact factor: 4.507

Review 3.  Primary care for women with intellectual disabilities.

Authors:  Joanne E Wilkinson; Mary C Cerreto
Journal:  J Am Board Fam Med       Date:  2008 May-Jun       Impact factor: 2.657

4.  Bone mineral loss and cognitive impairment: The PRESENT project.

Authors:  Hyun Goo Kang; Hyun Young Park; Han Uk Ryu; Seung-Han Suk
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.